Specific antioxidant properties of human serum albumin

被引:0
作者
Myriam Taverna
Anne-Lise Marie
Jean-Paul Mira
Bertrand Guidet
机构
[1] Université Paris Sud - Faculté de Pharmacie,CNRS UMR 8612
[2] Institut Galien Paris Sud,Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Universitaire Cochin
[3] Medical Intensive Care Unit,Broca
[4] Sorbonne Paris Cité,Hôtel Dieu
[5] Faculté de Médecine,Université Paris Descartes
[6] INSERM U1016/CNRS UMR 8104,Cochin Institute
[7] Hôpital Saint-Antoine,Assistance Publique des Hôpitaux de Paris
[8] Medical Intensive Care Unit,undefined
[9] Université Pierre et Marie Curie - Paris 6,undefined
[10] INSERM,undefined
[11] Unité de Recherche en Épidémiologie Systèmes d’Information et Modélisation (U707),undefined
来源
Annals of Intensive Care | / 3卷
关键词
Human serum albumin; Antioxidant force; Oxidized albumin; Critically ill patients;
D O I
暂无
中图分类号
学科分类号
摘要
Human serum albumin (HSA) has been used for a long time as a resuscitation fluid in critically ill patients. It is known to exert several important physiological and pharmacological functions. Among them, the antioxidant properties seem to be of paramount importance as they may be implied in the potential beneficial effects that have been observed in the critical care and hepatological settings. The specific antioxidant functions of the protein are closely related to its structure. Indeed, they are due to its multiple ligand-binding capacities and free radical-trapping properties. The HSA molecule can undergo various structural changes modifying its conformation and hence its binding properties and redox state. Such chemical modifications can occur during bioprocesses and storage conditions of the commercial HSA solutions, resulting in heterogeneous solutions for infusion. In this review, we explore the mechanisms that are responsible for the specific antioxidant properties of HSA in its native form, chemically modified forms, and commercial formulations. To conclude, we discuss the implication of this recent literature for future clinical trials using albumin as a drug and for elucidating the effects of HSA infusion in critically ill patients.
引用
收藏
相关论文
共 281 条
[1]  
Fanali G(2012)Human serum albumin: from bench to bedside Mol Aspects Med 33 209-290
[2]  
di Masi A(2004)A comparison of albumin and saline for fluid resuscitation in the intensive care unit N Engl J Med 350 2247-2256
[3]  
Trezza V(2008)The risk associated with hyperoncotic colloids in patients with shock Intensive Care Med 34 2157-2168
[4]  
Marino M(2006)Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study Crit Care Med 34 2536-2540
[5]  
Fasano M(2011)Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis Intensive Care Med 37 86-96
[6]  
Ascenzi P(1999)Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med 341 403-409
[7]  
Finfer S(2012)Does resuscitation with albumin-containing solutions improve mortality in sepsis? Ann Emerg Med 59 432-433
[8]  
Bellomo R(2011)The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis Crit Care Med 39 386-391
[9]  
Boyce N(2004)Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials Crit Care Med 32 2029-2038
[10]  
French J(2012)Colloids versus crystalloids for fluid resuscitation in critically ill patients Cochrane Database Syst Rev 6 CD000567-465